Top U.S. Healthcare Stocks to Watch, According to Mizuho

Mizuho highlighted a slate of U.S. healthcare stocks rated Outperform, citing clinical catalysts and improving operational/Commercial momentum. Key items include EyePoint (Duravyu Phase 3 LUGANO data expected Aug 2026) and Vaxcyte (VAX-31 Phase 3 OPUS-1 data expected Q4 2026), alongside Erasca (ERAS-0015 62% response rate in second-line-plus NSCLC; Phase 1/1b data expected H2 2026) and Arcutis (Zoryve Cream approval in under-2 AD expected early 2027). Price targets span roughly $26 (ERAS) to $163 (PCVX), suggesting a constructive skew for sector names but with likely limited immediate market-wide impact.

Analysis

The cleaner signal here is not “buy healthcare,” but that the market is being asked to separate cash-flow compounding from binary event risk. Names with visible operating levers over the next 1-3 quarters should outperform if the tape stays risk-on, because they can de-risk through execution rather than a single readout. That favors ARQT, EHC, LNTH, and to a lesser extent SOLV; the upside is less about narrative and more about proving that demand, utilization, or balance-sheet repair is accelerating.

The more speculative biology names are exposed to timing mismatch: the equity market may start discounting 12-24 month catalysts before there is any fundamental data to underwrite them. EYPT looks like a relative-value story versus OCUL, but the real question is whether specialist adoption translates into durable commercial economics; if not, the valuation gap is deserved. PCVX and ERAS have strong scientific setups, but they remain hostage to manufacturing, trial design, and eventual payer/label friction, which means the first good data can still be a poor stock entry if the bar has already moved.

Contrarian take: consensus is likely overpaying for “de-risking” in the early-stage names while underappreciating how hard it is to re-rate a stock before revenue or earnings inflect. The more interesting upside may be in the less glamorous operators where capacity constraints, cost-outs, and mix improvement can lift estimates every quarter. Falsifiers are straightforward: any slip in commercial traction, occupancy, or debt paydown in the next 1-2 quarters would compress multiples quickly; for the pipeline names, a timing delay or weaker-than-advertised data package would push them back into long-duration, dead-money territory.

Key Decisions for Investors

• Overweight LNTH and EHC on pullbacks over the next 1-3 months; these are the highest-quality risk/reward setups because the stocks can rerate on visible quarterly proof rather than distant binary events. Falsifier: weaker utilization or volume commentary in the next print.
• Take a starter long in ARQT only if channel checks confirm the sales-force expansion is converting into accelerating prescriptions; otherwise wait. This is a commercial-execution trade, not a science trade, and the upside comes from estimate revisions over the next 2-4 quarters.
• Avoid chasing EYPT, PCVX, and ERAS after the analyst note; if you want exposure, use small-sized call spreads or wait for closer-in catalyst windows. The risk is paying today for data that is still 12-24 months away and may slip.
• Set a watchlist trade on EYPT vs OCUL: go long EYPT / short OCUL only if the relative valuation gap remains wide into the 2026 catalyst window and specialist sentiment continues to improve. This is a spread trade, not an outright long, because the thesis depends on relative adoption, not just the trial readout.